VYNE Therapeutics Inc. — Director's Dealing 2025

Jan 23, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VYNE Therapeutics Inc. (VYNE)
CIK: 0001566044
Period of Report: 2025-01-21

Reporting Person: Harsch Mutya (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-21	Stock Option (right to buy)	$2.77	A	230000	Acquired	2035-01-20	Common Stock (230000)	Direct

Footnotes

F1: The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2026 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.